IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0129109
(2008-05-29)
|
등록번호 |
US-8158124
(2012-04-17)
|
발명자
/ 주소 |
- Sabbadini, Roger A.
- Garland, William A.
- Hansen, Genevieve
- Swaney, James Stephen
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 |
피인용 횟수 :
4 인용 특허 :
56 |
초록
Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.
대표청구항
▼
1. An isolated antibody, or antigen-binding fragment thereof, that binds lysophosphatidic acid (LPA) under physiological conditions, wherein the antibody or antigen-binding fragment thereof comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains,
1. An isolated antibody, or antigen-binding fragment thereof, that binds lysophosphatidic acid (LPA) under physiological conditions, wherein the antibody or antigen-binding fragment thereof comprises two immunoglobulin heavy chain variable domains and two immunoglobulin light chain variable domains, wherein: a. each immunoglobulin heavy chain variable domain comprises first, second, and third heavy chain complementarity determining regions (CDRs), wherein the first heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 56, 68, and 91, the second heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 57, 69, 79, and 92, and the third heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 58, 70, 80, 84, and 93; and,b. each immunoglobulin light chain variable domain comprises first, second, and third light chain CDRs, wherein the first light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 59, 71, 81, and 94, the second light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO; 60, 72, 82, and 95, and the third light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and 96. 2. An isolated antibody, or antigen-binding fragment thereof, according to claim 1 wherein the first heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 56, 68, and 91, the second heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 57, 69, 79, and 92, the third heavy chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 58, 70, 80, 84, and 93, the first light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 59, 71, 81, and 94, the second light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 60, 72, 82, and 95, and the third light chain CDR comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 61 and 96. 3. An isolated antibody, or antigen-binding fragment thereof, according to claim 1 selected from the group consisting of: a. an antibody, or antigen-binding fragment thereof, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 56, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 57, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 58, the first light chain CDR comprises the amino acid sequence of SEQ ID NO: 59, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 60, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 61;b. an antibody, or antigen-binding fragment thereof, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 68, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 69, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 70, the first light chain CDR comprises the amino acid sequences of SEQ ID NO: 71, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 72, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 61;c. an antibody, or antigen-binding fragment thereof, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 56, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 79, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 80, the first light chain CDR comprises the amino acid sequences of SEQ ID NO: 81, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 82, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 61;d. an antibody, or antigen-binding fragment thereof, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 56, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 79, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 84, the first light chain CDR comprises the amino acid sequences of SEQ ID NO: 81, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 82, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 61; ande. an antibody, or antigen-binding fragment thereof, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 91, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 92, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 93, the first light chain CDR comprises the amino acid sequences of SEQ ID NO: 94, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 95, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 96. 4. An anti-LPA antibody, or LPA-binding fragment thereof, according to claim 1 that is a humanized antibody or an antigen-binding fragment of a humanized antibody. 5. A composition comprising a carrier, optionally a pharmaceutically acceptable carrier, and an antibody, or antigen-binding fragment thereof, according to claim 1. 6. A composition according to claim 5, wherein the antibody, or antigen-binding fragment thereof, is a humanized antibody or antigen-binding fragment of a humanized antibody. 7. An isolated anti-LPA antibody, or LPA-binding fragment thereof, according to claim 1 wherein each immunoglobulin heavy chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 100, 104, 108, 112, and 116, and each immunoglobulin light chain variable domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 101, 105, 109, 113, and 117. 8. An anti-LPA antibody, or LPA-binding fragment thereof, according to claim 7 that is a humanized antibody or an antigen-binding fragment thereof, according to claim 7. 9. A composition comprising a carrier, optionally a pharmaceutically acceptable carrier, and an antibody, or antigen-binding fragment thereof, according to claim 7. 10. A composition according to claim 9 wherein the antibody, or antigen-binding fragment thereof, is a humanized antibody or antigen-binding fragment of a humanized antibody.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.